Byrne Asset Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
Other funds holding DGX
EB
AAMU
JWM
P
SAM
OIAM
SFA
TFA
Byrne Asset Management's DGX Position: Q2 2026 in Review
Byrne Asset Management reduced its Quest Diagnostics (DGX) stake by 7.6% in Q2 2026, selling an estimated $81.8K and leaving 5,078 shares worth $1.08M. The position accounts for 0.58% of the portfolio, ranked #45.
Byrne Asset Management first reported a position in DGX in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.31M in Q3 2025. 152 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- Byrne Asset Management held 5,078 shares of Quest Diagnostics worth $1.08M as of Q2 2026.
- Byrne Asset Management sold 417 Quest Diagnostics shares in Q2 2026, an estimated $81.8K.
- Quest Diagnostics made up 0.58% of Byrne Asset Management's portfolio in Q2 2026, its #45 holding.
- Byrne Asset Management first reported a position in Quest Diagnostics in Q4 2021 and has held it in 18 quarters since.
- Byrne Asset Management's Quest Diagnostics position peaked at $1.31M in Q3 2025.
- 152 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on Byrne Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.